
  
    
      
        Introduction_NNP
        Aggressive_NNP methods_NNS of_IN decreasing_VBG oxygen_NN consumption_NN ,_,
        such_JJ as_IN therapeutic_JJ musculoskeletal_NN blockade_NN ,_, are_VBP used_VBN for_IN
        patients_NNS with_IN marginal_JJ oxygen_NN delivery_NN associated_VBN with_IN
        cardiac_JJ and_CC respiratory_JJ insufficiency_NN ._. This_DT is_VBZ especially_RB
        true_JJ during_IN exotic_JJ mechanical_JJ ventilation_NN methods_NNS designed_VBN
        to_TO increase_VB efficiency_NN of_IN oxygen_NN utilization_NN and_CC decrease_VB
        peak_NN airway_NN pressures_NNS ._. In_IN addition_NN ,_, hemodynamic_JJ
        deterioration_NN from_IN the_DT effects_NNS of_IN unrestrained_JJ
        musculoskeletal_NN hyperactivity_NN can_MD precipitate_NN angina_NN ,_, heart_NN
        failure_NN ,_, and_CC cardiac_JJ arrhythmias_NNS by_IN increasing_VBG myocardial_NN
        work_NN and_CC oxygen_NN consumption_NN in_IN the_DT face_NN of_IN compromised_VBN
        coronary_JJ artery_NN output_NN [_NN 1_CD ]_NN ._. Escalating_NNP doses_NNS of_IN sedatives_NNS
        followed_VBN by_IN oppressive_JJ hemodynamic_JJ and_CC ventilatory_NN
        side-effects_JJ sometimes_RB provide_VB an_DT indication_NN for_IN
        therapeutic_JJ musculoskeletal_NN paralysis_NN to_TO rapidly_RB get_VB
        control_NN of_IN life_NN threatening_VBG agitation_NN syndromes_NNS ._. Brain_NNP wave_NN
        monitoring_VBG by_IN portable_JJ ,_, non-invasive_JJ computer_NN processed_VBN
        monitors_VBZ allows_VBZ quick_JJ recognition_NN of_IN some_DT brain_NN functions_NNS
        under_IN titrated_JJ suspended_VBN animation_NN in_IN real_JJ time_NN ,_,
        facilitating_VBG modulation_NN of_IN therapy_NN when_WRB the_DT visual_JJ clues_NNS of_IN
        neuronal_NN function_NN disappear_VB ._.
        The_DT classic_JJ EEG_NNP is_VBZ usually_RB recorded_VBN on_IN a_DT ponderous_JJ
        console_VB with_IN 8_CD to_TO 32_CD channels_NNS to_TO improve_VB sensitivity_NN ._.
        Difficulty_NNP using_VBG strip_NN chart_NN EEGs_NNP utilizing_VBG analog_NN
        technology_NN stimulated_VBN the_DT development_NN of_IN electronically_RB
        processed_VBN digital_JJ EEG_NNP monitoring_VBG ._. The_DT processed_VBN EEG_NNP does_VBZ
        not_RB require_VB as_IN many_JJ head_NN electrodes_NNS to_TO generate_VB a_DT
        satisfactory_JJ signal_NN that_WDT can_MD be_VB utilized_JJ for_IN useful_JJ
        clinical_JJ data_NNS in_IN the_DT ICU_NNP ._. Current_JJ practice_NN for_IN digitally_RB
        processed_VBN electroencephalography_NN is_VBZ to_TO non-invasively_JJ place_NN
        soft_JJ ,_, moist_NN contact_NN electrodes_NNS across_IN the_DT forehead_NN after_IN
        skin_NN preparation_NN with_IN an_DT anti-oil_JJ solution_NN ._. This_DT procedure_NN
        is_VBZ quick_JJ and_CC easy_JJ for_IN the_DT ICU_NNP staff_NN to_TO perform_VB and_CC requires_VBZ
        no_DT sophisticated_JJ training_NN ._.
        The_DT interpretation_NN of_IN an_DT EEG_NNP tracing_VBG involves_VBZ the_DT
        quantification_NN of_IN signal_NN strength_NN and_CC recognition_NN of_IN
        patterns_NNS [_NN 2_CD ]_NN ._. Quantification_NNP of_IN the_DT amplitude_NN and_CC
        frequency_NN can_MD be_VB effectively_RB accomplished_VBN with_IN any_DT signal_NN
        monitor_NN EEG_NNP ._. Pattern_NNP recognition_NN ,_, that_IN of_IN signal_NN
        morphology_NN ,_, spatial_NN and_CC temporal_JJ distribution_NN ,_, and_CC wave_NN
        form_NN reactivity_NN is_VBZ more_RBR difficult_JJ and_CC is_VBZ subject_JJ to_TO
        observer_NN interpretation_NN ._. These_DT parameters_NNS are_VBP not_RB evaluated_VBN
        very_RB effectively_RB by_IN raw_JJ signal_NN EEG_NNP monitors_VBZ ,_, but_CC some_DT
        progress_NN has_VBZ been_VBN made_VBN using_VBG computerized_JJ processed_VBN signal_NN
        EEGs_NNP ._. The_DT electrical_JJ activity_NN from_IN eye_NN movements_NNS ,_, facial_JJ
        muscles_NNS ,_, respiration_NN ,_, and_CC the_DT heart_NN 's_POS electrical_JJ limits_VBZ the_DT
        effectiveness_NN of_IN bedside_NN EEGs_NNP for_IN routine_JJ use_NN in_IN the_DT ICU_NNP ,_,
        but_CC under_IN neuromuscular_NN blockade_NN ,_, these_DT artifacts_NNS are_VBP
        minimized_VBN and_CC a_DT relatively_RB pure_JJ signal_NN is_VBZ obtained_VBN ._.
        Advantages_NNP of_IN the_DT processed_VBN EEG_NNP during_IN neuromuscular_NN
        blockade_NN are_VBP that_IN the_DT data_NNS are_VBP more_RBR easily_RB interpreted_VBN by_IN
        physicians_NNS not_RB specifically_RB trained_VBN in_IN
        electroencephalography_NN ._. These_DT trends_NNS may_MD then_RB be_VB
        interpreted_VBN more_RBR quickly_RB in_IN the_DT acute_JJ care_NN setting_NN ,_,
        resulting_VBG in_IN a_DT faster_RBR clinical_JJ intervention_NN where_WRB needed_VBN [_NN
        3_CD ]_NN ._.
      
      
        Practical_NNP electroencephalography_NN
        The_DT frequency_NN ranges_NNS of_IN brain_NN electrical_JJ activity_NN are_VBP
        divided_VBN as_IN follows_VBZ ,_, where_WRB the_DT amplitude_NN is_VBZ measured_VBN from_IN
        peak_NN to_TO peak_VB :_:
        Delta_NNP :_: <_NN 4_CD Hz_NNP
        Theta_NNP :_: 4_CD -_: 8_CD Hz_NNP
        Alpha_NNP :_: 8_CD -_: 12_CD Hz_NNP
        Beta_NN :_: ≥_NN 13_CD Hz_NNP
        The_DT continuum_NN from_IN wakefulness_NNS to_TO sleep_VB involves_VBZ a_DT
        progressive_JJ decrease_NN in_IN the_DT alpha_NN band_NN followed_VBN by_IN
        increased_VBN activity_NN in_IN the_DT beta_NN ,_, theta_NN and_CC delta_NN bands_NNS ._. The_DT
        alpha_NN rhythm_NN contains_VBZ waves_NNS of_IN 8_CD -_: 12_CD Hz_NNP and_CC is_VBZ very_RB
        responsive_JJ to_TO volitional_NN mental_JJ activity_NN ,_, increasing_VBG with_IN
        excitement_NN and_CC decreasing_VBG with_IN tranquility_NN ._. These_DT rhythms_NNS
        occur_VBP mainly_RB in_IN the_DT posterior_NN head_NN and_CC are_VBP the_DT predominant_NN
        brain_NN activity_NN in_IN the_DT normal_JJ brain_NN ._. The_DT beta_NN rhythm_NN occurs_VBZ
        in_IN the_DT prefrontal_NN regions_NNS and_CC has_VBZ been_VBN associated_VBN with_IN
        increased_VBN cognitive_JJ activity_NN ._. Higher_JJR levels_NNS of_IN beta_NN
        activity_NN have_VBP also_RB been_VBN associated_VBN with_IN anxiety_NN and_CC
        delirium_NN [_NN 4_CD ]_NN ._. During_IN the_DT induction_NN of_IN general_JJ anesthesia_NN ,_,
        transient_JJ beta_NN activity_NN can_MD also_RB indicate_VB the_DT initial_JJ
        anxiolytic_JJ and_CC amnestic_JJ stage_NN of_IN sedation_NN ._. Both_DT theta_NN and_CC
        delta_NN waves_NNS are_VBP seen_VBN in_IN stages_NNS three_CD and_CC four_CD of_IN normal_JJ
        sleep_NN ,_, and_CC not_RB in_IN awake_JJ adults_NNS [_NN 5_CD ]_NN ._.
      
      
        Interpretation_NNP of_IN signals_NNS :_: commonly_RB used_VBN medications_NNS
        in_IN the_DT ICU_NNP
        
          Narcotic_NNP analgesics_NNS
          
            Fentanyl_NNP and_CC morphine_NN
            The_DT effect_NN on_IN the_DT EEG_NNP of_IN intravenous_JJ fentanyl_NN in_IN
            doses_NNS of_IN 30_CD -_: 70_CD μg_NN /_NN kg_NN ,_, following_VBG premedication_NN with_IN oral_JJ
            lorazepam_NN 4_CD -_: 5_CD mg_NN or_CC 10_CD mg_NN intramuscular_NN morphine_NN ,_, was_VBD
            studied_VBN in_IN cardiac_JJ surgery_NN patients_NNS [_NN 6_CD ]_NN ._. Within_IN 1_CD min_NN ,_,
            the_DT normal_JJ alpha_NN rhythm_NN was_VBD replaced_VBN by_IN diffuse_NN theta_NN
            waves_NNS ,_, followed_VBD quickly_RB by_IN predominant_NN delta_NN activity_NN
            consistent_JJ with_IN anesthesia_NN ._. Lower_JJR doses_NNS of_IN fentanyl_NN
            resulted_VBD in_IN slowed_VBD alpha_NN activity_NN with_IN an_DT increase_NN in_IN
            theta_NN bands_NNS ._. In_IN the_DT cat_NN ,_, very_RB high_JJ levels_NNS of_IN fentanyl_NN ,_,
            in_IN the_DT range_NN of_IN 40_CD -_: 80_CD μg_NN /_NN kg_NN produced_VBD seizure-like_JJ
            activity_NN [_NN 7_CD ]_NN ._. The_DT EEG_NNP response_NN after_IN administration_NN of_IN
            morphine_NN is_VBZ similar_JJ to_TO that_DT of_IN fentanyl_NN ,_, and_CC resembles_VBZ
            the_DT pattern_NN demonstrated_VBN by_IN the_DT centrally_RB acting_VBG
            serotonin_NN uptake_NN inhibitors_NNS and_CC alpha-_NN 2_CD agonists_NNS such_JJ
            as_IN clonidine_NN [_NN 8_CD ]_NN ._.
          
          
            Meperidine_NNP
            Administration_NNP of_IN meperidine_NN in_IN usual_JJ analgesic_JJ
            intramuscular_NN doses_NNS ,_, produced_VBD a_DT picture_NN of_IN alpha_NN
            activity_NN voltage_NN reduction_NN and_CC the_DT appearance_NN of_IN slow_JJ
            waves_NNS of_IN intermediate_JJ voltage_NN ,_, consistent_JJ with_IN mild_JJ
            hypnosis_NNS [_NN 9_CD ]_NN ._.
          
          
            Benzodiazepines_NNP
            In_IN low_JJ doses_NNS ,_, the_DT anxiolytic_JJ action_NN of_IN
            benzodiazepines_NNS tends_VBZ to_TO decrease_VB the_DT percentage_NN of_IN
            alpha_NN activity_NN while_IN increasing_VBG the_DT prevalence_NN of_IN beta_NN
            waves_NNS over_IN 18_CD Hz_NNP [_NN 8_CD ]_NN ._. At_IN high_JJ doses_NNS ,_, theta_NN and_CC delta_NN
            activity_NN occurs_VBZ ,_, expressing_VBG the_DT sedative_NN activity_NN of_IN
            the_DT drug_NN ._.
          
          
            Midazolam_NNP
            In_IN one_CD study_NN of_IN ICU_NNP patients_NNS receiving_VBG midazolam_NN ,_,
            alpha_NN frequency_NN decreased_VBD and_CC beta_NN activity_NN became_VBD
            prominent_JJ ._. In_IN higher_JJR doses_NNS ,_, these_DT changes_NNS disappeared_VBD
            to_TO be_VB replaced_VBN by_IN delta_NN /_NN theta_NN activity_NN [_NN 10_CD ]_NN ._. The_DT onset_NN
            of_IN action_NN and_CC recovery_NN following_VBG intravenous_JJ
            administration_NN of_IN midazolam_NN is_VBZ rapid_JJ ._. When_WRB administered_VBN
            to_TO counteract_VB sedative_NN effect_NN ,_, the_DT benzodiazepine_NN
            antagonist_NN flumazinil_NN quickly_RB normalizes_NNS alpha_NN wave_NN
            activity_NN [_NN 11_CD ]_NN ._.
          
          
            Lorazepam_NNP
            EEG_NNP effects_NNS were_VBD relatively_RB slow_JJ in_IN onset_NN ,_, reaching_VBG
            base-line_JJ over_IN 30_CD min_NN after_IN infusion_NN ,_, and_CC with_IN a_DT
            prolonged_JJ duration_NN of_IN action_NN compared_VBN to_TO diazepam_NN ._.
            Increased_VBN activity_NN in_IN the_DT 13_CD -_: 30_CD Hz_NNP range_NN was_VBD prolonged_JJ ,_,
            followed_VBN by_IN increased_VBN sedative_NN activity_NN [_NN 12_CD ]_NN ._.
          
        
        
          Non-benzodiazepine_NNP hypnotics_NNS
          
            Propofol_NNP
            Administration_NNP of_IN propofol_NN for_IN anesthesia_NN initially_RB
            produced_VBD an_DT increase_NN in_IN the_DT amplitude_NN of_IN the_DT alpha_NN
            rhythm_NN ,_, followed_VBN by_IN an_DT increase_NN in_IN delta_NN and_CC theta_NN
            activity_NN and_CC burst_NN suppression_NN in_IN some_DT patients_NNS ,_,
            consistent_JJ with_IN anesthesia_NN [_NN 13_CD ]_NN ._. There_EX is_VBZ a_DT very_RB rapid_JJ
            onset_NN of_IN action_NN and_CC recovery_NN following_VBG intravenous_JJ
            administration_NN of_IN propofol_NN ._.
          
        
        
          Barbiturates_NNP
          
            Adjuncts_NNP to_TO sedation_NN
            An_DT alpha-_NN 2_CD adrenoreceptor_NN agonist_NN is_VBZ capable_JJ of_IN
            potentiating_VBG narcotic_JJ actions_NNS ._. EEG_NNP effects_NNS of_IN clonidine_NN
            are_VBP similar_JJ to_TO narcotics_NNS ._.
          
          
            Clonidine_NNP
            The_DT sedative_NN action_NN of_IN the_DT alpha-_NN 2_CD agonist_NN clonidine_NN
            is_VBZ commonly_RB appreciated_VBN in_IN the_DT ICU_NNP setting_VBG [_NN 15_CD ]_NN ._. The_DT
            EEG_NNP response_NN to_TO clonidine_NN is_VBZ similar_JJ to_TO that_DT of_IN
            morphine_NN and_CC thought_VBD to_TO have_VB a_DT similar_JJ central_JJ mode_NN of_IN
            action_NN [_NN 16_CD ]_NN ._. Clonidine_NNP increased_VBD the_DT time_NN rats_NNS spent_VBD
            in_IN the_DT drowsy_NN stage_NN of_IN wakefulness_NNS ,_, which_WDT corresponds_NNS
            to_TO behavioral_JJ sedation_NN and_CC inhibited_VBD REM_NNP sleep_VB for_IN 6_CD -_: 9_CD
            h_NN after_IN administration_NN [_NN 17_CD ]_NN ._.
          
        
      
      
        Interpretation_NNP of_IN signals_NNS :_: altered_VBN physiology_NN
        
          Carbon_NNP dioxide_NN
          Hypocarbia_NNP causes_NNS slowing_NN of_IN the_DT EEG_NNP ._. Small_JJ increases_NNS
          in_IN pCO_NN 
          2_CD (_( 5_CD -_: 20_CD %_NN above_IN normal_JJ )_) cause_VB decreased_VBD
          cerebral_JJ excitability_NN and_CC an_DT increased_VBN electroshock_NN
          seizure_NN threshold_NN ._. Higher_JJR levels_NNS (_( 30_CD %_NN above_IN normal_JJ )_)
          result_NN in_IN increased_VBN cerebral_JJ excitability_NN and_CC
          epileptiform_NN discharges_NNS ._. High_JJ levels_NNS (_( 50_CD %_NN above_IN normal_JJ )_)
          produce_VB EEG_NNP depression_NN [_NN 18_CD ]_NN ._.
        
        
          Oxygen_NNP
          Hyperoxia_NNP causes_VBZ a_DT low_JJ amplitude_NN ,_, fast_RB frequency_NN EEG_NNP
          pattern_NN characteristic_NN of_IN cerebral_JJ excitation_NN [_NN 19_CD ]_NN ._.
          Decreased_NNP brain_NN oxygenation_NN initially_RB causes_VBZ increased_VBD
          cerebral_JJ excitability_NN as_IN a_DT result_NN of_IN peripheral_JJ
          chemoreceptor_NN stimulation_NN and_CC its_PRP$ attendant_NN effects_NNS on_IN
          the_DT brain_NN 's_POS reticular_NN activating_VBG system_NN [_NN 20_CD ]_NN ._. If_IN hypoxia_NN
          persists_VBZ and_CC overwhelms_NNS compensatory_JJ systems_NNS ,_, diffuse_NN EEG_NNP
          slowing_VBG occurs_VBZ ,_, eventually_RB leading_VBG to_TO EEG_NNP silence_NN as_IN
          anoxia_NN approaches_NNS [_NN 21_CD ]_NN ._.
        
        
          Body_NN temperature_NN
          Hypothermia_NNP causes_NNS progressive_JJ slowing_NN of_IN brain_NN
          activity_NN at_IN core_NN temperatures_NNS below_IN 35_CD °_NN C_NNP ._. Complete_JJ
          electrical_JJ silence_NN occurs_VBZ with_IN profound_JJ hypothermia_NN
          (_( 7_CD -_: 20_CD °_NN c_SYM )_) [_NN 22_CD ]_NN ._.
        
        
          Sensory_NNP stimulation_NN
          In_IN the_DT awake_JJ patient_NN ,_, stimulation_NN of_IN the_DT senses_NNS
          usually_RB results_VBZ in_IN desynchronization_NN of_IN EEG_NNP patterns_NNS ,_,
          increased_VBN amplitude_NN and_CC increased_VBN frequency_NN [_NN 23_CD ]_NN ._. This_DT
          increase_NN in_IN activity_NN is_VBZ directly_RB correlated_JJ with_IN
          increased_VBN brain_NN metabolic_JJ activity_NN ._. High_JJ amplitude_NN delta_NN
          waves_NNS can_MD be_VB associated_VBN with_IN global_JJ cerebral_JJ dysfunction_NN ,_,
          indicating_VBG brain_NN damage_NN or_CC potentially_RB reversible_JJ
          metabolic_JJ suppression_NN of_IN cerebral_JJ function_NN ._.
        
        
          Blood_NNP flow_NN to_TO the_DT brain_NN
          EEG_NNP changes_NNS correlate_VBP well_RB with_IN blood_NN flow_NN to_TO the_DT
          cortex_NN ._. EEG_NNP changes_NNS begin_VBP to_TO occur_VB when_WRB blood_NN flow_NN
          decreases_NNS below_IN 30_CD %_NN of_IN normal_JJ [_NN 24_CD ]_NN ._. However_RB ,_, neurologic_JJ
          outcome_NN has_VBZ not_RB been_VBN demonstrated_VBN to_TO be_VB strictly_RB
          dependent_JJ on_IN EEG_NNP changes_NNS during_IN periods_NNS of_IN low_JJ flow_NN ,_, but_CC
          more_RBR on_IN duration_NN of_IN flow_NN deficits_NNS [_NN 25_CD ]_NN ._.
        
      
      
        Role_NNP of_IN bedside_NN electroencephalography_NN in_IN the_DT
        ICU_NNP
        The_DT therapeutic_JJ use_NN of_IN musculoskeletal_NN paralysis_NN with_IN
        non-depolarizing_JJ paralytic_JJ agents_NNS has_VBZ increased_VBN largely_RB
        because_IN of_IN the_DT advent_NN of_IN exotic_JJ mechanical_JJ ventilation_NN
        modes_NNS that_WDT require_VBP subjugation_NN of_IN the_DT patient_NN 's_POS normal_JJ
        ventilation_NN activity_NN [_NN 26_CD ]_NN ._. During_IN such_JJ ventilation_NN modes_NNS ,_,
        paralysis_NN may_MD benefit_VB ventilation_NN efficacy_NN by_IN decreasing_VBG
        chest_NN wall_NN muscle_NN tension_NN and_CC peak_NN airway_NN pressure_NN ._. In_IN
        addition_NN ,_, the_DT disparate_JJ inhalation_NN and_CC exhalation_NN timing_NN
        necessary_JJ for_IN these_DT modes_NNS is_VBZ difficult_JJ for_IN the_DT patient_NN to_TO
        tolerate_VB ,_, and_CC paralysis_NN is_VBZ necessary_JJ to_TO avoid_VB the_DT patient_NN
        fighting_VBG against_IN this_DT unequal_JJ inhalation_NN :_: exhalation_NN (_( I_NN :_: E_NNP )_)
        ratio_NN ._. Other_JJ uses_NNS for_IN therapeutic_JJ musculoskeletal_NN paralysis_NN
        such_JJ as_IN `_`` chemical_NN restraint_NN '_'' to_TO protect_VB health_NN care_NN
        personnel_NNS from_IN violent_JJ behavior_NN [_NN 27_CD ]_NN ,_, and_CC the_DT decreasing_VBG
        of_IN cerebral_JJ blood_NN flow_NN during_IN unstable_JJ intracranial_NN
        pressure_NN following_VBG head_NN injury_NN [_NN 28_CD ]_NN ,_, are_VBP relatively_RB
        rare_JJ ._.
        Agitation_NNP episodes_NNS that_WDT threaten_VBP hemodynaimc_NN stability_NN
        are_VBP becoming_VBG more_RBR common_JJ in_IN the_DT ICU_NNP as_IN a_DT larger_JJR range_NN of_IN
        sick_JJ patients_NNS are_VBP identified_VBN are_VBP cared_VBN for_IN ._. Life_NNP
        threatening_VBG agitation_NN is_VBZ usually_RB signalled_JJ by_IN escalating_VBG
        musculoskeletal_NN hyperactivity_NN in_IN the_DT face_NN of_IN increasing_VBG
        sedative_NN administration_NN ._. Eventually_RB a_DT point_NN is_VBZ reached_VBN
        where_WRB the_DT direct_JJ effects_NNS of_IN agitation_NN combined_VBN with_IN
        suppressive_JJ side-effects_JJ of_IN pharmacologic_JJ agents_NNS threaten_VBP
        respiratory_JJ and_CC hemodynamic_JJ stability_NN ._. Agitated_NNP delirium_NN
        syndromes_NNS ,_, such_JJ as_IN ethanol_NN withdrawal_NN ,_, may_MD constitute_VB
        genuine_JJ medical_JJ emergencies_NNS as_IN they_PRP have_VBP potentially_RB
        disastrous_JJ hemodynamic_JJ and_CC metabolic_JJ consequences_NNS and_CC may_MD
        become_VB an_DT indication_NN for_IN therapeutic_JJ musculoskeletal_NN
        paralysis_NN [_NN 29_CD ]_NN ._.
        Severe_NNP agitation_NN syndromes_NNS such_JJ as_IN delirium_NN tremens_NNS
        alter_VBP physiology_NN and_CC can_MD precipitate_NN hemodynamic_JJ
        deterioration_NN by_IN increasing_VBG musculoskeletal_NN activity_NN and_CC
        metabolic_JJ activity_NN to_TO the_DT point_NN where_WRB increasing_VBG cardiac_JJ
        output_NN cannot_NN be_VB sustained_VBN by_IN cardiac_JJ physiology_NN [_NN 30_CD ]_NN ._.
        This_DT can_MD precipitate_NN angina_NN ,_, heart_NN failure_NN ,_, and_CC cardiac_JJ
        arrhythmias_NNS by_IN increasing_VBG myocardial_NN work_NN and_CC oxygen_NN
        consumption_NN in_IN the_DT face_NN of_IN a_DT compromised_VBN coronary_JJ artery_NN
        output_NN [_NN 27_CD ]_NN ._. In_IN addition_NN ,_, musculoskeletal_NN hyperactivity_NN
        produces_VBZ metabolic_JJ acidosis_NNS that_WDT can_MD precipitate_NN
        arrhythmias_NNS and_CC compromise_NN oxygen_NN delivery_NN ._. Hyperactivity_NNP
        in_IN muscle_NN groups_NNS not_RB used_VBN to_TO increased_VB work_NN can_MD cause_VB
        myoglobinuria_NN and_CC renal_JJ failure_NN as_RB well_RB [_NN 31_CD ]_NN ._.
        If_IN agitation_NN resists_VBZ the_DT titrated_JJ effects_NNS of_IN
        rapid-acting_JJ ,_, short-duration_JJ sedatives_NNS and_CC becomes_VBZ so_RB
        severe_JJ that_IN hemodynamic_JJ stability_NN is_VBZ threatened_VBN ,_,
        therapeutic_JJ musculoskeletal_NN paralysis_NN ,_, endotracheal_NN
        intubation_NN and_CC mechanical_JJ ventilation_NN ,_, and_CC titrated_JJ
        hemodynamic_JJ support_NN may_MD be_VB necessary_JJ to_TO prevent_VB
        cardiorespiratory_NN collapse_NN ._. True_JJ `_`` suspended_VBN animation_NN '_'' can_MD
        be_VB induced_VBN to_TO gain_VB complete_JJ control_NN of_IN the_DT situation_NN early_JJ ,_,
        rather_RB than_IN chance_NN the_DT increased_VBN hazards_NNS of_IN partial_JJ control_NN
        in_IN unstable_JJ circumstances_NNS ._. Unlike_IN benzodiazepines_NNS that_WDT
        cause_VBP musculoskeletal_NN relaxation_NN ,_, non-depolarizing_JJ ,_,
        neuromuscular_NN ,_, end_NN plate_NN neurotransmission_NN antagonists_NNS
        affect_VBP therapeutic_JJ musculoskeletal_NN paralysis_NN ._. Suspended_NNP
        animation_NN using_VBG musculoskeletal_NN paralytic_JJ agents_NNS will_MD
        effectively_RB stop_VB the_DT effects_NNS of_IN muscular_JJ hyperactivity_NN on_IN
        end_NN organs_NNS ._. It_PRP is_VBZ also_RB extremely_RB important_JJ to_TO remember_VB that_IN
        underneath_IN therapeutic_JJ paralysis_NN lies_VBZ unprotected_JJ cerebral_JJ
        function_NN ._. Therefore_RB ,_, the_DT amount_NN of_IN sedation_NN needed_VBN to_TO
        ameliorate_NN the_DT helpless_JJ feeling_NN of_IN paralysis_NN in_IN the_DT awake_JJ
        state_NN is_VBZ virtually_RB impossible_JJ to_TO determine_VB from_IN any_DT
        information_NN gained_VBN by_IN a_DT physical_JJ examination_NN or_CC an_DT
        objective_NN sedation_NN scale_NN such_JJ as_IN the_DT Ramsay_NNP Score_NN [_NN
        32_CD ]_NN ._.
        For_IN the_DT intensivist_NN ,_, advantages_NNS of_IN the_DT computer_NN
        processed_VBD EEG_NNP are_VBP that_IN the_DT data_NNS are_VBP more_RBR easily_RB interpreted_VBN
        by_IN physicians_NNS not_RB specifically_RB trained_VBN in_IN
        electroencephalography_NN [_NN 33_CD ]_NN ._. This_DT technology_NN uses_VBZ a_DT single_JJ
        bipolar_NN lead_NN to_TO accentuate_NN trends_NNS in_IN brain_NN wave_NN activity_NN
        (_( mostly_RB frontal_JJ cortex_NN )_) ,_, which_WDT may_MD then_RB be_VB interpreted_VBN more_RBR
        quickly_RB in_IN the_DT acute_JJ care_NN setting_NN ,_, resulting_VBG in_IN a_DT faster_RBR
        clinical_JJ intervention_NN where_WRB needed_VBN ._. Sophistication_NNP in_IN
        bedside_NN EEG_NNP hardware_NN is_VBZ increasing_VBG ,_, with_IN multi-channel_JJ EEG_NNP
        recording_NN ,_, various_JJ data_NNS reduction_NN functions_NNS such_JJ as_IN the_DT
        Bispectral_NNP Index_NNP ,_, and_CC evoked_JJ potential_JJ analysis_NN becoming_VBG
        available_JJ to_TO the_DT ICU_NNP ._.
        Modern_NNP cerebral_JJ function_NN monitors_VBZ survey_NN brain_NN
        electrical_JJ activity_NN in_IN real_JJ time_NN and_CC reflect_VB changes_NNS in_IN
        brain_NN activity_NN caused_VBN by_IN sedatives_NNS and_CC other_JJ therapeutics_NNS [_NN
        34_CD ]_NN ._. There_EX is_VBZ accumulating_VBG evidence_NN that_IN regimens_NNS utilizing_VBG
        continuous_JJ infusion_NN of_IN sedative_NN agents_NNS can_MD be_VB effectively_RB
        titrated_JJ ,_, assuring_VBG patient_NN comfort_NN and_CC neuronal_NN stability_NN
        under_IN paralysis_NN ,_, while_IN the_DT search_NN for_IN underlying_VBG pathology_NN
        and_CC effective_JJ treatment_NN programs_NNS follows_VBZ [_NN 35_CD ,_, 36_CD ]_NN ._.
        Different_JJ classifications_NNS and_CC combinations_NNS of_IN sedatives_NNS ,_,
        analgesics_NNS or_CC antipsychotics_NNS can_MD be_VB tried_VBN until_IN the_DT
        combination_NN that_WDT brings_VBZ about_IN the_DT most_RBS appropriately_RB calm_VB
        cerebral_JJ function_NN tracing_VBG is_VBZ discovered_VBN ._.
      
      
        Potential_JJ practical_JJ application_NN of_IN bedside_NN
        electroencephalography_NN
        Modern_NNP miniaturized_VBN electroencephalographic_JJ monitors_VBZ
        (_( Fig_NNP 1_LS )_) can_MD be_VB positioned_VBN at_IN the_DT bedside_NN ,_, visible_JJ to_TO the_DT
        clinical_JJ team_NN but_CC out_IN of_IN the_DT way_NN of_IN nursing_NN procedures_NNS ._.
        They_PRP are_VBP attached_VBN to_TO the_DT patient_NN 's_POS frontal_JJ cranium_NN by_IN
        non-invasive_JJ patches_NNS similar_JJ to_TO electrocardiogram_NN (_( EKG_NNP )_)
        leads_NNS ._. The_DT EEG_NNP monitor_NN depicts_VBZ gross_JJ brain_NN wave_NN activity_NN in_IN
        an_DT easily_RB interpretable_JJ fashion_NN ,_, allowing_VBG quick_JJ recognition_NN
        of_IN sedation_NN adequacy_NN during_IN therapeutic_JJ neuromuscular_NN
        blockade_NN when_WRB the_DT visual_JJ clues_NNS disappear_VBP ._. Some_DT objective_NN
        measurement_NN of_IN cerebral_JJ function_NN can_MD be_VB frequently_RB and_CC
        rapidly_RB assessed_VBN before_IN the_DT patient_NN undergoes_NNS therapeutic_JJ
        obtundation_NN ,_, or_CC specifically_RB neuromuscular_NN blockade_NN ,_, then_RB
        the_DT effects_NNS of_IN sedation_NN can_MD be_VB followed_VBN in_IN real_JJ time_NN (_( Figs_NNP
        2_CD and_CC 3_LS )_) ._. The_DT effects_NNS of_IN specific_JJ sedatives_NNS such_JJ as_IN
        midazolam_NN (_( Figs_NNP 4_CD and_CC 5_LS )_) ,_, lorazepam_NN (_( Fig_NNP 6_CD )_) ,_, and_CC fentanyl_NN
        (_( Fig_NNP 7_CD )_) can_MD be_VB assessed_VBN in_IN real_JJ time_NN ._. The_DT effect_NN of_IN
        extremely_RB deep_JJ sedation_NN differs_VBZ from_IN clinical_JJ brain_NN death_NN
        by_IN the_DT presence_NN of_IN delta_NN waves_NNS and_CC the_DT absence_NN of_IN EKG_NNP
        artifacts_NNS (_( Fig_NNP 8_CD )_) ._. A_DT sedated_JJ patient_NN undergoing_VBG
        neuromuscular_NN blockade_NN who_WP is_VBZ vigorously_RB stimulated_VBN shows_VBZ a_DT
        brief_JJ `_`` waking_VBG '_'' pattern_NN ,_, demonstrating_VBG the_DT sensitivity_NN of_IN
        monitoring_VBG cerebral_JJ responsiveness_NNS when_WRB the_DT visual_JJ clues_NNS
        are_VBP not_RB present_JJ (_( Fig_NNP 9_CD )_) ._. Adequacy_NNP of_IN sedation_NN can_MD be_VB
        titrated_JJ in_IN real_JJ time_NN ,_, reflecting_VBG relatively_RB small_JJ changes_NNS
        in_IN therapy_NN ,_, such_JJ as_IN inadvertent_JJ oversedation_NN ,_, on_IN brain_NN
        function_NN (_( Fig_NNP 10_CD )_) ._.
        Once_RB a_DT patient_NN with_IN compromised_VBN respiratory_JJ or_CC vital_JJ
        functions_NNS is_VBZ placed_VBN on_IN life_NN support_NN hardware_NN ,_, sophisticated_JJ
        monitoring_NN devices_NNS such_JJ as_IN continuous_JJ pulse_NN oximetry_NN ,_,
        continuous_JJ mixed_JJ venous_JJ oximetry_NN ,_, and_CC capnography_NN
        effectively_RB monitor_VB hemodynamic_JJ and_CC ventilatory_NN parameters_NNS ._.
        However_RB ,_, for_IN patients_NNS with_IN intrinsic_JJ or_CC iatrogenically_RB
        initiated_VBN brain_NN failure_NN ,_, it_PRP is_VBZ exceedingly_RB difficult_JJ to_TO
        monitor_VB the_DT combined_VBN effects_NNS of_IN delirium_NN and_CC oppressive_JJ
        sedation_NN regimens_NNS on_IN neuronal_NN function_NN once_RB visual_JJ clues_NNS
        are_VBP removed_VBN ._. Musculoskeletal_NNP paralysis_NN does_VBZ not_RB attenuate_NN
        the_DT effects_NNS of_IN catecholamine_NN release_NN ._. In_IN the_DT past_NN ,_, sedation_NN
        has_VBZ been_VBN titrated_JJ under_IN paralysis_NN until_IN tachycardia_NN and_CC
        hypertension_NN normalize_VB ,_, suggesting_VBG that_DT patient_NN comfort_NN has_VBZ
        been_VBN achieved_VBN ._. This_DT is_VBZ an_DT inaccurate_JJ way_NN of_IN determining_VBG
        patient_NN comfort_NN under_IN the_DT effects_NNS of_IN paralysis_NN ,_, and_CC may_MD be_VB
        unreliable_JJ in_IN ICU_NNP patients_NNS on_IN medications_NNS like_IN beta_NN
        adrenergic_JJ antagonists_NNS to_TO control_VB heart_NN rate_NN ,_, and_CC
        sympathomimetic_JJ drugs_NNS such_JJ as_IN dopamine_NN or_CC dobutamine_NN to_TO
        support_VB hemodynamics_NNS ._. The_DT advent_NN of_IN cerebral_JJ function_NN
        monitoring_VBG has_VBZ improved_VBN on_IN this_DT old_JJ method_NN dramatically_RB ._.
        The_DT processed_VBN EEG_NNP is_VBZ potentially_RB valuable_JJ in_IN the_DT ICU_NNP
        because_IN of_IN its_PRP$ ability_NN to_TO continuously_RB monitor_VB the_DT end_NN
        result_NN of_IN therapeutics_NNS at_IN the_DT neuronal_NN level_NN ,_, improving_VBG the_DT
        timing_NN of_IN therapeutic_JJ intervention_NN by_IN physicians_NNS not_RB timing_NN
        of_IN therapeutic_JJ intervention_NN by_IN physicians_NNS not_RB trained_VBN in_IN
        the_DT interpretation_NN of_IN standard_JJ analog_NN strip_NN EEGs_NNP ._.
        The_DT most_RBS persistent_JJ argument_NN against_IN cerebral_JJ function_NN
        monitoring_VBG in_IN the_DT ICU_NNP is_VBZ the_DT issue_NN of_IN cost_NN versus_CC benefit_NN ._.
        Cerebral_NNP function_NN monitoring_VBG as_IN an_DT accurate_JJ method_NN of_IN
        assessing_VBG and_CC controlling_VBG sedation_NN during_IN therapeutic_JJ
        musculoskeletal_NN paralysis_NN seems_VBZ desirable_JJ ,_, but_CC there_EX are_VBP
        virtually_RB no_DT data_NNS yet_RB demonstrating_VBG that_IN such_JJ monitoring_NN
        significantly_RB alters_NNS patient_NN outcome_NN ._. There_EX are_VBP those_DT who_WP
        require_VBP `_`` hard_JJ '_'' data_NNS supporting_VBG any_DT therapeutic_JJ modality_NN
        before_IN they_PRP will_MD embrace_VB it_PRP ._. This_DT is_VBZ as_IN it_PRP should_MD be_VB ._.
        However_RB ,_, this_DT argument_NN assumes_VBZ the_DT ready_JJ availability_NN of_IN
        convincing_JJ ,_, substantive_JJ evidence_NN supporting_VBG an_DT improved_VBN
        outcome_NN with_IN the_DT use_NN of_IN the_DT test_NN modality_NN ._. When_WRB a_DT modality_NN
        resides_VBZ on_IN the_DT frontier_NN of_IN medical_JJ practice_NN and_CC there_EX are_VBP
        no_DT hard_JJ data_NN available_JJ ,_, it_PRP seems_VBZ logical_JJ to_TO look_VB for_IN
        convincing_JJ data_NNS other_JJ than_IN those_DT which_WDT are_VBP necessarily_RB
        outcome_NN related_VBN as_IN justification_NN ._. Perhaps_RB the_DT assurance_NN
        that_IN the_DT patient_NN is_VBZ comfortable_JJ under_IN sedation_NN regimens_NNS
        instituted_VBN when_WRB visual_JJ clues_NNS of_IN neuronal_NN function_NN disappear_VB
        is_VBZ a_DT substantive_JJ enough_JJ argument_NN until_IN hard_JJ data_NNS from_IN
        future_JJ research_NN projects_NNS come_VBP along_IN ._.
        In_IN deciding_VBG how_WRB much_JJ we_PRP can_MD afford_VB to_TO monitor_VB ,_, we_PRP must_MD
        also_RB consider_VB what_WP we_PRP cannot_NN afford_VB not_RB to_TO monitor_VB ._. Massive_JJ
        overdoses_NNS from_IN multiple_JJ sedatives_NNS ,_, analgesics_NNS ,_, and_CC even_RB
        musculoskeletal_NN paralytic_JJ agents_NNS are_VBP a_DT real_JJ possibility_NN
        when_WRB regimens_NNS have_VBP no_DT objective_NN guidance_NN ._. Conversely_RB ,_,
        skimpy_JJ sedation_NN regimens_NNS ,_, arbitrarily_RB instituted_VBN from_IN a_DT
        lack_NN of_IN the_DT same_JJ objective_NN guidelines_NNS ,_, may_MD cause_VB lasting_JJ
        psychiatric_JJ complications_NNS in_IN patients_NNS paralyzed_VBN and_CC awake_JJ
        at_IN the_DT same_JJ time_NN ._. Real_JJ damage_NN to_TO patients_NNS resulting_VBG from_IN
        therapeutic_JJ misadventures_NNS during_IN periods_NNS when_WRB cerebral_JJ
        function_NN monitoring_NN is_VBZ not_RB assessed_VBN are_VBP not_RB only_RB possible_JJ ,_,
        they_PRP are_VBP likely_JJ ._. The_DT risk_NN to_TO the_DT patient_NN from_IN non-invasive_JJ
        cerebral_JJ functioning_NN is_VBZ non-existent_JJ and_CC the_DT potential_JJ
        benefits_NNS at_IN least_JJS theoretically_RB possible_JJ ._. The_DT relatively_RB
        small_JJ purchase_NN price_NN for_IN one_CD monitor_VB spreads_NNS out_IN quickly_RB if_IN
        the_DT monitor_NN can_MD be_VB used_VBN for_IN numerous_JJ patients_NNS in_IN an_DT ICU_NNP
        setting_VBG ._. It_PRP seems_VBZ likely_JJ that_IN the_DT protection_NN and_CC
        preservation_NN of_IN man_NN 's_POS most_RBS valuable_JJ organ_NN is_VBZ entirely_RB
        justified_JJ [_NN 37_CD ]_NN ._.
      
    
  
